Scientific Reports (Sep 2023)

Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study

  • Maria Amelia Carlos Souto Maior Borba,
  • Paula de Mendonça Batista,
  • Milena Falcão Almeida,
  • Maria Aparecida do Carmo Rego,
  • Fernando Brandão Serra,
  • Julio Cesar Barbour Oliveira,
  • Karina Nakajima,
  • Guilherme Silva Julian,
  • Gilberto Amorim

DOI
https://doi.org/10.1038/s41598-023-43131-9
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

Abstract In Brazil, data on the management of triple negative breast cancer (TNBC) as well as the burden of the disease in terms of health care resources utilization (HCRU) are scarce. To characterize the treatment patterns and HCRU associated with the management of Brazilian TNBC patients from the perspective of the private healthcare setting. Patients with at least one claim related to ICD-10 C50 from January 2012 until December 2017, and at least one claim for breast cancer treatment were assessed from a private claims database and classified as early and locally advanced, or metastatic. All patients with hormone and/or targeted therapy were excluded. Three thousand and four patients were identified, of which 82.8% were diagnosed in early and locally advanced stages. For early and locally advanced TNBC patients, 75.3% were treated in an adjuvant setting, mainly with anthracycline regimes. For mTNBC patients, bevacizumab regimens were the main treatment prescribed. More than 48% of mTNBC patients were switched to a second line of treatment. HCRU was higher for mTNBC patients when compared to early and locally advanced patients, with higher costs for metastatic disease management. The treatment setting has little influence on the HCRU pattern or the cost of disease management. The highest burden of disease was observed for metastatic management.